These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19690506)

  • 1. Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: a call for evidence.
    Levy-Lahad E
    Genet Med; 2009 Sep; 11(9):620-1. PubMed ID: 19690506
    [No Abstract]   [Full Text] [Related]  

  • 2. Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.
    Lynce F; Isaacs C
    J Natl Compr Canc Netw; 2016 Jun; 14(6):809-12. PubMed ID: 27283172
    [No Abstract]   [Full Text] [Related]  

  • 3. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
    Levy-Lahad E; Lahad A; King MC
    J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
    [No Abstract]   [Full Text] [Related]  

  • 5. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
    Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
    Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unknown significance.
    Couzin-Frankel J
    Science; 2014 Dec; 346(6214):1167-70. PubMed ID: 25477439
    [No Abstract]   [Full Text] [Related]  

  • 8. [BRCAmutations more frequent in people of Jewish ancestry].
    Menko FH; Rosenberg EH; van der Kolk LE
    Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30875152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two BRCA1/2 founder mutations in Jews of Sephardic origin.
    Sagi M; Eilat A; Ben Avi L; Goldberg Y; Bercovich D; Hamburger T; Peretz T; Lerer I
    Fam Cancer; 2011 Mar; 10(1):59-63. PubMed ID: 21063910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.
    Chodick G; Struewing JP; Ron E; Rutter JL; Iscovich J
    Eur J Med Genet; 2008; 51(2):141-7. PubMed ID: 18158280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial communication and cascade testing among relatives of BRCA population screening participants.
    Lieberman S; Lahad A; Tomer A; Koka S; BenUziyahu M; Raz A; Levy-Lahad E
    Genet Med; 2018 Nov; 20(11):1446-1454. PubMed ID: 29595811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
    Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
    Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
    Barnes-Kedar I; Bernstein-Molho R; Ginzach N; Hartmajer S; Shapira T; Magal N; Kalis ML; Peretz T; Shohat M; Basel-Salmon L; Friedman E; Bazak L; Goldberg Y
    Breast Cancer Res Treat; 2018 Nov; 172(1):151-157. PubMed ID: 30014164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.
    Rubinstein WS; Jiang H; Dellefave L; Rademaker AW
    Genet Med; 2009 Sep; 11(9):629-39. PubMed ID: 19606050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.
    Distelman-Menachem T; Shapira T; Laitman Y; Kaufman B; Barak F; Tavtigian S; Friedman E
    Fam Cancer; 2009; 8(2):127-33. PubMed ID: 18798010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community attitudes towards a Jewish community BRCA1/2 testing program.
    Cousens N; Kaur R; Meiser B; Andrews L
    Fam Cancer; 2017 Jan; 16(1):17-28. PubMed ID: 27480161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities.
    Augustyn AM; Agostino NM; Namey TL; Nair S; Martino MA
    Breast Cancer Res Treat; 2011 Sep; 129(2):629-34. PubMed ID: 21607582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.
    D'Andrea E; Marzuillo C; De Vito C; Di Marco M; Pitini E; Vacchio MR; Villari P
    Genet Med; 2016 Dec; 18(12):1171-1180. PubMed ID: 27906166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Screening for Inherited Predisposition to Breast and Ovarian Cancer.
    Manchanda R; Lieberman S; Gaba F; Lahad A; Levy-Lahad E
    Annu Rev Genomics Hum Genet; 2020 Aug; 21():373-412. PubMed ID: 32315550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.